MAP2K7 and prostate carcinoma: However, the rate of mutations in Ras/MEK/ERK pathway in clinical prostate cancer is very low; only up to 7% of clinical samples have activating point mutations of Ras and around 4 % are positive for BRAF, the most common activating mutation of RAF [57].